ABT vs GLUE · P/E 25, rev $44.33B vs rev $13.2M
Abbott Laboratories (ABT) versus Monte Rosa Therapeutics Inc (GLUE) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Monte Rosa Therapeutics Inc (GLUE) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported GLUE revenue for 2026-06-30 was $13.2M. Net income was -$87.9M. GLUE currently screens at market cap $1.56B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. GLUE currently screens at market cap $1.56B.
Not investment advice. Open the ABT and GLUE stock pages for the full models.
Not investment advice.